reports
BioNTech schließt Übernahme von CureVac N.V. samt damit verbundener Na...
BioNTech schließt Übernahme von CureVac N.V. samt damit verbundener Nachangebotsfrist ab und stärkt so die einzigartige Position im mRNA-Feld BioNTech hat das Umtauschangebot zur Übernahme von CureVac abgeschlossenDie Übernahme von CureVac ergänzt BioNTechs Fähigkeiten und unternehmenseigene Technologien im Bereich mRNA-Design, Verabreichungsformulierungen und mRNA-HerstellungInsgesamt wurden etwa 86,75 Prozent der CureVac-Aktien angedient; BioNTech geht davon aus, dass der obligatorische Erwerb der verbleibenden CureVac-Aktien im Januar 2026 im Rahmen der zuvor angekündigten Nach-Angebots-...
BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offer...
BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field BioNTech has completed its exchange offer to acquire CureVacAcquisition complements BioNTech’s capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturingIn total, approximately 86.75% of CureVac shares were tendered; BioNTech expects to complete the compulsory acquisition of the remaining CureVac shares in January 2026 as part of the previously announced post-offer reorganizationCureVac will continue to operate unde...
Euronext announces December 2025 quarterly review results of the PSI®
Euronext announces December 2025 quarterly review results of the PSI® Lisbon – 10 December 2025 Euronext today announced the results of the annual review for the PSI®, which will be implemented after markets close on Friday 19 December 2025 and will be effective from Monday 22 December 2025. Results of the December 2025 quarterly review PSI® No changes in the composition of the index The Independent Supervisor retains the right to change the published selection, for instance in the case of a removal due to a takeover, until the publication of the final data after close of Wednesday 17 ...
Erste Ergebnisse aus BioNTechs und BMS’ globaler Phase-2-Studie mit bi...
Erste Ergebnisse aus BioNTechs und BMS’ globaler Phase-2-Studie mit bispezifischem PD-L1xVEGF-A-Antikörperkandidat Pumitamig zeigten ermutigende Anti-Tumor-Aktivität bei fortgeschrittenem dreifach negativem Brustkrebs Zwischenergebnisse der globalen klinischen Phase-2-Studie bei lokal fortgeschrittenem/metastasiertem dreifach negativem Brustkrebs (triple-negative breast cancer, „TNBC“) zeigten eine ermutigende Anti-Tumor-Aktivität für Pumitamig (BNT327/BMS986545) in Kombination mit Chemotherapie bei Patientinnen und Patienten in der Erst- oder ZweitlinienbehandlungPumitamig in Kombination m...
BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data fo...
BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus chemotherapy in first- and second-line patientsPumitamig plus chemotherapy achieved confirmed objective response rate (cORR) of 61.5%, unconfirmed ORR (uORR) of 71.8% and disease control rate (DCR) of 92.3% irrespec...
- ING Helpdesk
BioNTechs und OncoC4s selektiver Treg-Modulatorkandidat Gotistobart er...
BioNTechs und OncoC4s selektiver Treg-Modulatorkandidat Gotistobart erzielte klinisch relevanten Gesamtüberlebensvorteil bei Patientinnen und Patienten mit zuvor behandeltem Plattenepithelkarzinom der Lunge Der selektive Treg-Modulatorkandidat Gotistobart (BNT316/ONC-392) zeigte eine Verringerung des Sterberisikos um mehr als die Hälfte im Vergleich zur Standard-Chemotherapie sowie ein kontrollierbares Sicherheitsprofil im ersten von zwei Abschnitten der globalen, klinischen Phase-3-Studie PRESERVE-003 bei Patientinnen und Patienten mit Plattenepithelkarzinom der Lunge (squamous non-small c...
BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Be...
BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard of care chemotherapy and a manageable safety profile in the first of two stages of the global Phase 3 trial PRESERVE-003 in patients with squamous non-small cell lung cancer (“sqNSCLC”) who have progressed on prior immunotherapy plus chemotherapyMedian OS with gotistobart ha...
Euronext announces volumes for November 2025
Euronext announces volumes for November 2025 Euronext announces volumes for November 2025 Amsterdam, Athens, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 5 December 2025 – Euronext, the leading European capital market infrastructure, today announced trading volumes for November 2025. Monthly and historical volume tables are available at this address: CONTACTS ANALYSTS & INVESTORS – Investor Relations Judith Stein 97 Margaux Kurver 03 MEDIA – Europe Andrea Monzani 13 Sandra Machado 7 Belgium ...
BioNTech erfüllt Mindestannahmebedingungen im Rahmen des Umtauschangeb...
BioNTech erfüllt Mindestannahmebedingungen im Rahmen des Umtauschangebots für CureVac-Aktien Mindestannahmebedingung für das Angebot wurde erfüllt; es wurden vor Ablauf der ursprünglichen Angebotsfrist insgesamt 184.071.410 CureVac-Aktien angedient, was etwa 81,74 % der ausgegebenen und im Umlauf befindlichen CureVac-Aktien entsprichtDie Nachangebotsfrist hat begonnen und endet am Donnerstag, den 18. Dezember 2025, um 6:01 Uhr MEZ (0:01 Uhr EST) MAINZ, Deutschland, 3. Dezember 2025 – h SE (Nasdaq: BNTX, „BioNTech“) gab heute bekannt, dass 184.071.410 Aktien der CureVac N.V. (Nasdaq: CVA...
BioNTech Achieves Minimum Condition in CureVac Exchange Offer
BioNTech Achieves Minimum Condition in CureVac Exchange Offer The minimum condition for the offer has been satisfied, with 184,071,410 shares of CureVac, representing approximately 81.74% of CureVac’s issued and outstanding shares, tendered prior to the expiration of the initial offering periodThe subsequent offering period has commenced and will expire at 12:01 a.m. Eastern Time on Thursday, December 18, 2025 MAINZ, Germany, December 3, 2025 – (Nasdaq: BNTX, “BioNTech”) announced today that 184,071,410 shares of CureVac N.V. (Nasdaq: CVAC, “CureVac”), representing approximately 81.74% o...
BioNTech Shares Progress on Exchange Offer for CureVac Shares and High...
BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration Offer set to expire at 9:00 am Eastern Time on December 3, 2025, with CureVac shareholders advised to tender their shares by 6:00 pm Eastern Time on December 2, 2025, due to operational deadlines.Exchange ratio of 0.05363 of a BioNTech American Depositary Share (“ADS”) for each CureVac share, determined based on the volume-weighted average price of BioNTech ADSs over the 10 trading days ending November 25, 2025.CureVac shareholders approved matters related to ...
BioNTech informiert über Fortschritte im Rahmen des Umtauschangebots f...
BioNTech informiert über Fortschritte im Rahmen des Umtauschangebots für CureVac-Aktien und weist auf Ablauf des Angebots am 3. Dezember 2025 um 15 Uhr MEZ hin Ablauf des Angebots am 3. Dezember 2025 um 15 Uhr MEZ (9:00 Uhr EST); CureVac-Aktionärinnen und -Aktionären wird empfohlen, ihre Aktien aufgrund operativer Fristen bis spätestens 3. Dezember 2025, 0:00 Uhr MEZ (2. Dezember 2025 um 18:00 Uhr EST) anzudienenErmittlung des Umtauschverhältnisses von 0,05363 einer BioNTech American Depositary Share („ADS“) je CureVac-Aktie auf Grundlage des volumengewichteten Durchschnittskurses der BioN...
Generali: 1 director
A director at Generali sold 15,811 shares at 33.222EUR and the significance rating of the trade was 91/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...
Euronext announces the results of the tender offer on existing EUR 202...
Euronext announces the results of the tender offer on existing EUR 2026 Bonds NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OF AMERICA OR THE DISTRICT OF COLUMBIA (THE “UNITED STATES”) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”)) OR IN OR INTO ANY OTH...
- Farid Bitari
- Nicolas David
ENX EURONEXT NV
BNP BNP PARIBAS SA CLASS A
ZURN ZURICH INSURANCE GROUP LTD
LSEG LONDON STOCK EXCHANGE GROUP PLC
NOKIA NOKIA OYJ
ISP INTESA SANPAOLO S.P.A.
PKN POLSKI KONCERN NAFTOWY ORLEN S.A.
UCG UNICREDIT S.P.A.
ASSA B ASSA ABLOY AB CLASS B
ALG ALLEGRO.EU SA
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
ZAB ZABKA GROUP
- Farid Bitari
- Nicolas David
ENX EURONEXT NV
BNP BNP PARIBAS SA CLASS A
ZURN ZURICH INSURANCE GROUP LTD
LSEG LONDON STOCK EXCHANGE GROUP PLC
NOKIA NOKIA OYJ
ISP INTESA SANPAOLO S.P.A.
PKN POLSKI KONCERN NAFTOWY ORLEN S.A.
UCG UNICREDIT S.P.A.
ASSA B ASSA ABLOY AB CLASS B
ALG ALLEGRO.EU SA
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
ZAB ZABKA GROUP
- Julian Dobrovolschi
Euronext announces the success of the voluntary share exchange tender ...
Euronext announces the success of the voluntary share exchange tender offer to acquire ATHEX Group Euronext announces the success of the voluntary share exchange tender offer to acquire ATHEX Group Strong shareholder support reflects confidence in the future growth trajectory of Euronext ATHEX to join Euronext’s best-in-class trading and post-trade technology, boosting the visibility and attractiveness of the Greek market on an international scaleThis result reinforces Euronext’s leadership in Europe and advances the Group’s diversification strategy Amsterdam, Brussels, Dublin, Lisbon, Mi...
EURONEXT N.V. announces the successful outcome of its voluntary share ...
EURONEXT N.V. announces the successful outcome of its voluntary share exchange tender offer made to acquire the ordinary registered shares of HELLENIC EXCHANGES – ATHENS STOCK EXCHANGE S.A. (“ATHEX”) ANNOUNCEMENT EURONEXT N.V. (“Euronext” or the “Offeror”) announces the successful outcome of its voluntary share exchange tender offer made to acquire the ordinary registered shares of HELLENIC EXCHANGES – ATHENS STOCK EXCHANGE S.A. (“ATHEX”) 19 November 2025 INTRODUCTION In accordance with article 23 of Greek Law 3461/2006, as amended and in force (the “Law”), Euronext announces the succes...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.